Skip to main content
Premium Trial:

Request an Annual Quote

WellGen Raises $3M in Series B Financing

NEW YORK, Feb. 16 (GenomeWeb News) - WellGen closed a $3-million Series B funding round, the company said today.

 

The capital will be used to begin clinical studies in humans under its obesity and inflammation programs, said the company in a statement.

 

The lead investor was Amphion Innovations. The company said investors included "new and existing shareholders."

 

Further details were not provided.

 

New Brunswick, NJ- based WellGen develops technologies to screen the effect of food on the expression of genes associated with human disease.

The Scan

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.

Gut Microbiomes Allow Bears to Grow to Similar Sizes Despite Differing Diets

Researchers in Scientific Reports find that the makeup of brown bears' gut microbiomes allows them to reach similar sizes even when feasting on different foods.

Finding Safe Harbor in the Human Genome

In Genome Biology, researchers present a new approach to identify genomic safe harbors where transgenes can be expressed without affecting host cell function.

New Data Point to Nuanced Relationship Between Major Depression, Bipolar Disorder

Lund University researchers in JAMA Psychiatry uncover overlapping genetic liabilities for major depression and bipolar disorder.